These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 22459347)

  • 1. Intermodality comparison between 3D perfusion CT and 18F-FDG PET/CT imaging for predicting early tumor response in patients with liver metastasis after chemotherapy: preliminary results of a prospective study.
    Kim DH; Kim SH; Im SA; Han SW; Goo JM; Willmann JK; Lee ES; Eo JS; Paeng JC; Han JK; Choi BI
    Eur J Radiol; 2012 Nov; 81(11):3542-50. PubMed ID: 22459347
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combination of 18F-FDG PET/CT and diffusion-weighted MR imaging as a predictor of histologic response to neoadjuvant chemotherapy: preliminary results in osteosarcoma.
    Byun BH; Kong CB; Lim I; Choi CW; Song WS; Cho WH; Jeon DG; Koh JS; Lee SY; Lim SM
    J Nucl Med; 2013 Jul; 54(7):1053-9. PubMed ID: 23670899
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Continued pemetrexed and platin-based chemotherapy in patients with malignant pleural mesothelioma (MPM): value of 18F-FDG-PET/CT.
    Schaefer NG; Veit-Haibach P; Soyka JD; Steinert HC; Stahel RA
    Eur J Radiol; 2012 Jan; 81(1):e19-25. PubMed ID: 21129871
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Imaging the early response to chemotherapy in advanced lung cancer with diffusion-weighted magnetic resonance imaging compared to fluorine-18 fluorodeoxyglucose positron emission tomography and computed tomography.
    Tsuchida T; Morikawa M; Demura Y; Umeda Y; Okazawa H; Kimura H
    J Magn Reson Imaging; 2013 Jul; 38(1):80-8. PubMed ID: 23239463
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multifunctional profiling of non-small cell lung cancer using 18F-FDG PET/CT and volume perfusion CT.
    Sauter AW; Winterstein S; Spira D; Hetzel J; Schulze M; Mueller M; Pfannenberg C; Claussen CD; Klotz E; Hann von Weyhern C; Horger MS
    J Nucl Med; 2012 Apr; 53(4):521-9. PubMed ID: 22414637
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Early PET/CT scan is more effective than RECIST in predicting outcome of patients with liver metastases from colorectal cancer treated with preoperative chemotherapy plus bevacizumab.
    Lastoria S; Piccirillo MC; Caracò C; Nasti G; Aloj L; Arrichiello C; de Lutio di Castelguidone E; Tatangelo F; Ottaiano A; Iaffaioli RV; Izzo F; Romano G; Giordano P; Signoriello S; Gallo C; Perrone F
    J Nucl Med; 2013 Dec; 54(12):2062-9. PubMed ID: 24136935
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Feasibility of [18F]FDG-PET and coregistered CT on clinical target volume definition of advanced non-small cell lung cancer.
    Messa C; Ceresoli GL; Rizzo G; Artioli D; Cattaneo M; Castellone P; Gregorc V; Picchio M; Landoni C; Fazio F
    Q J Nucl Med Mol Imaging; 2005 Sep; 49(3):259-66. PubMed ID: 16172572
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Response to chemotherapy predicts survival following resection of hepatic colo-rectal metastases in patients treated with neoadjuvant therapy.
    Small RM; Lubezky N; Shmueli E; Figer A; Aderka D; Nakache R; Klausner JM; Ben-Haim M
    J Surg Oncol; 2009 Feb; 99(2):93-8. PubMed ID: 19065637
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prospective evaluation of CECT and 18F-FDG-PET/CT in detection of hepatic metastases.
    D'souza MM; Sharma R; Mondal A; Jaimini A; Tripathi M; Saw SK; Singh D; Mishra A; Tripathi RP
    Nucl Med Commun; 2009 Feb; 30(2):117-25. PubMed ID: 19057427
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A prospective diagnostic accuracy study of 18F-fluorodeoxyglucose positron emission tomography/computed tomography, multidetector row computed tomography, and magnetic resonance imaging in primary diagnosis and staging of pancreatic cancer.
    Kauhanen SP; Komar G; Seppänen MP; Dean KI; Minn HR; Kajander SA; Rinta-Kiikka I; Alanen K; Borra RJ; Puolakkainen PA; Nuutila P; Ovaska JT
    Ann Surg; 2009 Dec; 250(6):957-63. PubMed ID: 19687736
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic value of 18f-fluorodeoxyglucose positron emission tomography-computed tomography in predicting survival in patients with unresectable metastatic melanoma to the liver undergoing yttrium-90 radioembolization.
    Piduru SM; Schuster DM; Barron BJ; Dhanasekaran R; Lawson DH; Kim HS
    J Vasc Interv Radiol; 2012 Jul; 23(7):943-8. PubMed ID: 22609292
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 18F-FDG PET and CT/MRI in oral cavity squamous cell carcinoma: a prospective study of 124 patients with histologic correlation.
    Ng SH; Yen TC; Liao CT; Chang JT; Chan SC; Ko SF; Wang HM; Wong HF
    J Nucl Med; 2005 Jul; 46(7):1136-43. PubMed ID: 16000282
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Feasibility of integrated CT-liver perfusion in routine FDG-PET/CT.
    Veit-Haibach P; Treyer V; Strobel K; Soyka JD; Husmann L; Schaefer NG; Tschopp A; Hany TF
    Abdom Imaging; 2010 Oct; 35(5):528-36. PubMed ID: 19593563
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Computer-aided detection (CAD) and assessment of malignant lesions in the liver and lung using a novel PET/CT software tool: initial results.
    Hahn S; Heusner T; Zhou X; Zhan Y; Peng Z; Hamami M; Forsting M; Bockisch A; Antoch G
    Rofo; 2010 Mar; 182(3):243-7. PubMed ID: 19859858
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel strategy for a cocktail 18F-fluoride and 18F-FDG PET/CT scan for evaluation of malignancy: results of the pilot-phase study.
    Iagaru A; Mittra E; Yaghoubi SS; Dick DW; Quon A; Goris ML; Gambhir SS
    J Nucl Med; 2009 Apr; 50(4):501-5. PubMed ID: 19289439
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diffusion weighted MRI and 18F-FDG PET/CT in non-small cell lung cancer (NSCLC): does the apparent diffusion coefficient (ADC) correlate with tracer uptake (SUV)?
    Regier M; Derlin T; Schwarz D; Laqmani A; Henes FO; Groth M; Buhk JH; Kooijman H; Adam G
    Eur J Radiol; 2012 Oct; 81(10):2913-8. PubMed ID: 22197090
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 18F-FDG PET/CT as a staging procedure in primary stage II and III breast cancer: comparison with conventional imaging techniques.
    Koolen BB; Vrancken Peeters MJ; Aukema TS; Vogel WV; Oldenburg HS; van der Hage JA; Hoefnagel CA; Stokkel MP; Loo CE; Rodenhuis S; Rutgers EJ; Valdés Olmos RA
    Breast Cancer Res Treat; 2012 Jan; 131(1):117-26. PubMed ID: 21935602
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prediction model of chemotherapy response in osteosarcoma by 18F-FDG PET and MRI.
    Cheon GJ; Kim MS; Lee JA; Lee SY; Cho WH; Song WS; Koh JS; Yoo JY; Oh DH; Shin DS; Jeon DG
    J Nucl Med; 2009 Sep; 50(9):1435-40. PubMed ID: 19690035
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quantitative p retreatment VOI analysis of liver metastases. (99m)Tc-MAA SPECT/CT and FDG PET/CT in relation with treatment response to SIRT.
    Van de Wiele C; Stellamans K; Brugman E; Mees G; De Spiegeleer B; D'Asseler Y; Beels L; Maes A
    Nuklearmedizin; 2013; 52(1):21-7. PubMed ID: 23358716
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Monitoring response to antiangiogenic treatment and predicting outcomes in advanced hepatocellular carcinoma using image biomarkers, CT perfusion, tumor density, and tumor size (RECIST).
    Jiang T; Kambadakone A; Kulkarni NM; Zhu AX; Sahani DV
    Invest Radiol; 2012 Jan; 47(1):11-7. PubMed ID: 21512396
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.